Obesity Featured Articles

  1. Designing Successful Cell And Gene Therapy Trials 9/10/2025

    Designing cell and gene therapy trials requires specialized strategies to navigate unique complexities, ensuring successful and compliant development.

  2. The Path Forward In Oncology Trials 9/10/2025

    A comprehensive site support model is crucial for navigating the complexities of modern oncology trials and accelerating drug development.

  3. Creating Operational Efficiency And Competitive Edge 9/10/2025

    Site networks offer a strategic approach to oncology clinical trials by accelerating study startup and expanding access to diverse patient populations.

  4. Developing Community-Based & Trial-Naïve Sites: The Real ROI 9/9/2025

    Trial-naïve sites, when supported with infrastructure, training, and network integration, represent a critical yet underused opportunity to expand patient access and accelerate recruitment.

  5. AI-Powered Strategy Is Redefining Patient Recruitment Performance 9/9/2025

    This AI-powered platform is helping CROs and sponsors tackle the unsolved challenge they've faced for decades: clinical trials that launch late, recruit slowly, and miss enrollment targets.

  6. How Community-Based Research Models Expand Access 9/9/2025

    As momentum continues to grow in neurology research, how can community-based research models help overcome recruitment and retention challenges in complex areas like Alzheimer's?

  7. Are Pragmatic Trials The Patient Recruitment Solution We've Been Looking For? 9/9/2025

    TransCelerate's Rob DiCicco reintroduces the "pragmatic trial" design concept, discusses its potential benefits, and provides resources for its integration.

  8. The New FDA Era Of Radical Transparency And Pervasive Oversight 9/9/2025

    The first half of 2025 has been transformative for biopharmaceutical quality and regulatory affairs, with the FDA leading the charge with four significant changes. Curadian Group's David Grote discusses implications for all four.

  9. GLP-1 Ocular Safety Monitoring At Point-Of-Need 9/8/2025

    Regulators are sharpening their focus on ocular safety in GLP-1 receptor agonist trials following emerging evidence linking semaglutide to non-arteritic anterior ischemic optic neuropathy (NAION).

  10. Redesigning Oncology Trials Around Tumor Vulnerability: The Rise of WEE1 And DDR Strategies 9/8/2025

    As clinical progress with DNA damage response (DDR) continues to evolve, research must respond with adaptive models, smarter combinations, and biomarker-informed patient selection.